PALVELLA THERAPEUTICS, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- PVLAPalvella Therapeutics, Inc.0Calm
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
Signing up patientsPhase 215 patientsMain results: Aug 2027 - PVLAPalvella Therapeutics, Inc.0Calm
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Running, no new patientsPhase 351 patientsMain results: Jan 14, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
48 sales (1 not pre-planned) · 0 purchases
- Goin KathleenChief Operating Officer · Oct 21, 2026Sold 2,043 sharesabout $253 thousand · pre-planned
- Goin KathleenChief Operating Officer · Oct 21, 2026Sold 1,663 sharesabout $208 thousand · pre-planned
- Goin KathleenChief Operating Officer · Oct 21, 2026Sold 607 sharesabout $77 thousand · pre-planned
- JENKINS GEORGE MBoard member · Oct 14, 2026Sold 476 sharesabout $58 thousand · pre-planned
- JENKINS GEORGE MBoard member · Oct 14, 2026Sold 2,072 sharesabout $254 thousand · pre-planned
- JENKINS GEORGE MBoard member · Oct 14, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 5, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Nov 5, 2026
- Other newsNews report (8-K)Oct 28, 2026
- Quarterly reportQuarterly report (10-Q)Aug 4, 2026
- Shared quarterly results; Shared information with investorsNews report (8-K)Aug 4, 2026